| |
Move beyond a single set of forecast numbers and embrace uncertainty in healthcare forecasting: IQVIA’s Forecast Horizon is enabling pharma to broaden their analysis and drive deeper insights. Learn more.
|
|
Today's Big NewsOct 5, 2022 |
| By Fraiser Kansteiner Wednesday, the U.S. Department of Health and Human Services (HHS) said it’s throwing down $290 million to lock up an undisclosed amount of Amgen’s blood disorder med Nplate, which is approved to treat blood cell injuries linked to acute radiation syndrome (ARS) in kids and adults. |
|
|
|
By Frank Diamond Since COVID-19 surfaced, the cases of influenza dropped to historic lows. That might not be the case this year as a “twindemic” could develop. |
By James Waldron Novo Nordisk added the final piece to the puzzle the Danish drugmaker wanted to complete before submitting its once-weekly insulin icodec to regulators next year. |
By Conor Hale Roche received the first FDA approval for a companion diagnostic test to identify patients carrying this HER2-low status—a more precise characterization of breast tumors that was previously more binary, relying largely on positive and negative labels. |
By Angus Liu Merck’s Keytruda is well established as the standard treatment for newly diagnosed metastatic non-small cell lung cancer. For PD-1 latecomer Jemperli from GSK, an impressive trial showing met the tough bar established by the Merck blockbuster. |
By Nick Paul Taylor GSK’s anti-TIM-3 antibody is moving into a pivotal trial after hitting the mark in the midphase portion of the study, cementing the Big Pharma’s status as a front-runner in a thinning field featuring Novartis. |
By Paige Minemyer Three health insurance CEOs earned spots on Fortune's annual ranking of Most Powerful Women in Business, with one topping the list for the second straight year. |
By Conor Hale Before Inc. and Saritasa are working to make hospital visits a little easier for children and young teenagers by giving them a pre-op tour in virtual reality. |
By Max Bayer Eiger won't be nabbing emergency use authorization for its COVID treatment after all. The company says the FDA rejected the pathway citing concerns about the trial and the general state of the pandemic in the U.S. |
By Kevin Dunleavy Merck has opened a new secondary packaging facility to churn out vaccines and biologics. It also broke ground on a plant that will produce inhalers and is set for completion in 2026. |
By Heather Landi Medical group Desert Oasis Healthcare has jumped on board to pilot Google Health's clinical software Care Studio. It marks Google Health's third provider partnership, and its first outpatient collaboration, for its clinician-facing search tool that harmonizes healthcare data from different sources. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we talk about how how frequent cyberattacks are impacting patient care and what hospitals and health systems can do to shore up their defenses. Also under discussion is how social drivers of health are finally being recognized by the CMS. |
|
|---|
|
|
|
Monday, October 17, 2022 | 11am ET / 8am PT Join the Omic Revolution! Register now to attend a FREE webinar to leverage deep multiomic data integration for target and biomarker discovery.
|
|
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| WhitepaperLearn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT Data |
| WhitepaperRead about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperThis paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
| Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
| Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
| eBookImprove patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
